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Introduction: Parkinson disease (PD) is the common neurodegenerative disease. a-Synuclein
(ASN), main aggregating protein in neural cells of CNS in PD, was found in peripheral ﬂuids.
Testing ASN in plasma is potential test for diagnose PD, but previous studies are controver-
sial. The aim of this study was to investigate if plasma ASN level may be a valuable
biomarker, is the level of plasma ASN concentration different in various motor subtypes
of diseases, is there a relation between the level of plasma ASN and the severity of motor
symptoms.
Methods: Patients with PD hospitalized in Neurology Department, Medical College were
performed sequencing the 8th and 9th exon of GBA gene. Next plasma ASN level was tested
in 58 patients with sequenced GBA gene and in 38 healthy volunteers (HV), matched by the
age (respectively 68.43 vs. 64.57 years of age) and sex (female %, respectively: 43.10 vs.44.74).
Patients were assessed with the scales: UPDRS (II, III, IV), Hoehn–Yahr (HY) and qualiﬁed to
PIGD or TD subtype. For homogeneity of the group patients with GBA mutation were
excluded from the analysis.
Results: The ASN level did not differ between patients and HV (respectively: 4.53 vs. 3.73 ng/
ml) and between patients with different subtypes. There was inverse correlation between
ASN and HY in PIGD subtype.
Conclusions: Plasma ASN level is not valuable marker of the disease. It does not differ in
subtypes of the disease. There is relation between plasma ASN level and the severity of the
disease in PIGD subtype.
© 2017 Published by Elsevier Sp. z o.o. on behalf of Polish Neurological Society.
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Parkinson's disease (PD) is a common neurodegenerative
disease characterized by a wide range of clinical features.
Because of heterogeneous motor manifestations of early PD
some authors suggest three subtypes of the disease: postural
instability and gait difﬁculty (PIGD), tremor dominant (TD) and
with mixed symptoms (MPD) [1]. PIGD is associated with worse
prognosis, poorer response to treatment, greater risk of
dementia and higher prevalence of autonomic disturbances
[2]. PD patients differ also in presence and intensity of
numerous non-motor symptoms. The most common of them
are depression and cognitive impairment. Parkinson's disease
dementia (PDD) is the next clinical entity of PD spectrum
diseases [3].
The pathogenesis of PD is associated with aggregation of
pathologically conformed proteins. The main aggregating
protein in PD is a-synuclein (ASN) [4]. ASN has many
physiological functions in central nervous system (CNS). In
vivo and in vitro experiments have demonstrated that ASN is
released from the cells to the peripheral ﬂuids [5,6]. This was
the trigger to search ASN as the biomarker of PD. Finding the
objective marker for PD is very important because making an
accurate diagnosis of PD is difﬁcult, especially in early stages of
the disease. Even 15–25% of patients with parkinsonian
symptoms and signs do not have correct diagnosis [7].
The level of ASN in PD patients was investigated in blood
[6,8–21] and cerebrospinal ﬂuid (CSF) [22,23], but the results of
these studies are controversial. The total plasma ASN in PD
patients was found to be higher [9,15], lower [13,16], or similar
to the control group [8,11,12,17,24]. Other forms of ASN, such as
oligomers [10] or phosphorylated ASN [11–13] were measured
also, but the result were also inconclusive. The reasons for that
could be associated with different origin of ASN in plasma.
Some amount of ASN can originate from erythrocytes and
platelets [20]. Min Shi et al. measured the only exosomal ASN,
and found that this form of ASN, originated from CNS, is
signiﬁcantly higher in PD patients than in healthy controls
[19]. In other study analysing the ratio of ASN oligomers to
total erythrocytes' proteins, they explored that it is higher in
PD patients than in healthy controls [14].
However there are only a few studies analysing the relation
between ASN level in plasma and motor subtypes of PD (PIGD,
TD, MPD), cognitive impairment and the presence of other
non-motor symptoms [8].
Heterozygous carrier status of glucocerebrosidase (GBA)
mutation is thought nowadays to be the most important
genetic risk factor for idiopathic PD [25]. The relation between
ASN and GBA on the cellular and molecular level has been
proven [26]. It is connected with more intensive neurodegen-
erative process by forming toxic forms of ASN, which
inﬂuences clinical picture of PD [27]. There are no publications
concerning the relation between the plasma ASN concentra-
tion and GBA mutation in PD. However the level of plasma ASN
oligomers is higher in patients with GD and some other
lysosomal diseases than in healthy volunteers. Interesting is
the fact that there was no difference of plasma ASN oligomers
level between healthy volunteers and patients with GD who
were treated with enzyme replacement therapy (ERT) unlikeGD patients without ERT. Moreover the authors mentioned
that carriers of GBA mutation with PD had higher level of
plasma ASN oligomers than healthy volunteers, but the data
were not yet published [18]. In other publication they showed
that the relation of dimers/monomers originated from
erythrocytes in patients with GD is higher than in healthy
volunteers. Dimerisation is restrictive stage of ASN oligomer-
isation [28]. And ﬁnally in the last study they proved reverse
correlation between the level of plasma ASN oligomers ant the
activity of GBA in leukocytes of GD patients [29].
The aim of the study was to evaluate plasma ASN level as a
valuable biomarker of PD, and to answer the questions of
whether the level of plasma ASN concentration is different in
various motor subtypes of diseases (PIGD, TD, MPD) and is
there a relation between the level of plasma ASN and if there is
a relation between the level of plasma ASN and cognitive
impairment or depressive symptoms. Additional aim was to
analyze the relation of plasma ASN level between GBA
mutation carriers and non-carriers with PD.
2. Material and methods
The investigations were carried out on patients diagnosed
with PD, hospitalized at the Subdivision of Movement
Disorders in Clinical Department of Neurology, University
Hospital, etc. in years 2007–2014.
All patients were physically examined by a neurologist and
underwent head MR to exclude vascular disease which could
cause the Parkinsonism. The actual severity of motor
symptoms and the stage of the disease in PD patients group
were assessed with UPDRS part II, III and IV as well as Hoehn–
Yahr (HY) Scale. Jankovic method was used to classify patient
to different motor subtypes of disease (PIGD, TD, MPD) based
on UPDRS, part II and III [1]. The Hamilton Depression Rating
Scale (HDRS) and Minimental State Examination (MMSE) were
used to make the screening for depressive symptoms and
cognitive impairment respectively. The blood samples were
taken from all of the patients for sequencing the 8th and 9th
GBA gene exon with the method preventing ampliﬁcation of
GBA pseudogene, which was the subject of previous publica-
tion [30].
Healthy volunteers were invited to the study as the control
group (CG). They were selected on the basis of gender and age
to match the plasma ASN evaluation group. The subjects of
CG group were unrelated members of the patients' families,
their minders as well as persons accompanying the patients.
They were examined physically by neurologist, than they
were assessed with screening tests for cognitive impairment
and depressive symptoms. In the CG, there were persons with
no neurological disease and severe systemic illness. 5 ml of
blood was collected from all participants to test the level of
plasma ASN by ELISA. All subjects gave their written
informed consent. The study was approved by Bioethics
Committee of Medical College, etc. (KBET/106/B/2013, date
28.11.2013).
Inclusion criteria for PD patients:
- Parkinson's disease diagnosed according to QSBB criteria;
- age above 40 years;
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individually for stages I and II of the study.
Exclusion criteria for PD patients:
- cancer or any other acute or chronic condition demanding
proper therapies (antibiotics, steroids, anti-inﬂammatory
drugs, immunosuppressants or immunomodulators, etc.);
- cardio-vascular or respiratory diseases effecting in circula-
tory or respiratory insufﬁciency, regardless of the disease
intensity;
- hepatic or renal failure or clinical failure of any other organ,
diagnosed or suspected in laboratory tests (signiﬁcantly high
transaminase, creatinine, TSH, aggravated anaemia, gran-
ulopenia, etc.);
- intensive cerebral ischaemia (basal ganglia and/or white
matter) in neuroimaging, suggestive of vascular parkinson-
ism (in accordance with clinics);
- concomitant CNS diseases (other neurodegenerative condi-
tions, different than PD, motor impairments, SM, epilepsy,
etc.);
- concomitant psychiatric disorders demanding treatment
with psychotropic drugs;
- history of heavy metal poisoning;
- history of exposure to toxic substances.
Inclusion criteria for the control group:
- age above 40 years;
- informed written consent.
Exclusion criteria for the control group:
- manifestations of parkinsonism;
- other diagnosed or suspected conditions demanding pharma-
cological treatment except for well controlled hypertension.
2.1. Evaluation of plasma ASN
In order to evaluate plasma ASN concentrations 5 ml circular
blood was taken from each of the patients and the healthy
controls. Within 15 min the material was centrifuged for
15 min at acceleration 1500  g and temperature 4 8C. The
plasma collected was stored at 80 8C. Protein concentration
was determined by ELISA immunoenzymatic test, following
the product protocol, catalogue no. KHB0061 by Invitrogen.
During ﬁrst incubation, serum ASN bound with solid phase
monoclonal antibodies and with the speciﬁc polyclonal rabbit
antibodies of the liquid phase. Next, after washing out of
excessive components, speciﬁc polyclonal rabbit antibodies,
marked with radish peroxidase, were added where binding
with the rabbit antibodies, they complemented a four-layer
‘‘sandwich’’. Following the second incubation and another
washing out of the excessive components, a substrata was
added to the bound enzyme in order to generate colour. The
colour intensity is directly proportional to ASN concentration.
ASN levels were given in ng/ml. Each test included two assays
where a median value was calculated. If concentration scores
obtained from two assays differed substantially, another assaywas performed and the extreme values rejected. The labora-
tory tests were performed at the Department of Proteomics, . . .
and ﬁnanced through a grant by the . . . K/ZDS/002288.
2.2. Statistical analysis
Calculations were made with the use of IBM SPSS 23.0. software.
Evaluation of validity of distribution of the assessed variables
with the normal distribution used the Kolmogorov–Smirnov
chart and Shapiro–Wilk test. In case a variable showed
distribution conforming with normal distribution, comparison
made use of t-Student test for two groups and ANOVA for
multipleones. If the variables showed distribution different than
the normal one, comparison of groups made use of U Mann–
Whitney test (2 groups) or Kruskal–Wallis test (3 or more groups).
For evaluation of relation between the quantitative variables,
Pearson correlation coefﬁcient was used (for variables valid for
normal distribution)orSpearmantest (if distribution ofvariables
differed from the normal distribution or for random variables).
Chi-square test was used to determine the relation between the
ordinal and nominal variable and V-Cramer coefﬁcient to
evaluate the effect size. In order to assess the diagnostic
usefulness of ASN, the receiver operating characteristic curve
(ROC) was drawn. The accepted level of statistical signiﬁcance
was p < 0.05. In order to preserve the group homogeneity and to
eliminate any possible effect of GBA gene mutation, further
assays to evaluate relation between plasma ASN and the clinical
data, excluded the patients with mutation.
3. Results
3.1. Demographic data
138 patients with PD were screened for GBA mutation. In the
whole group of PD patients 16 (11.6%) were carriers of GBA
variants. In 5 (3.6%) patients it was N370S mutation and in 11
(7.9%) were T369M polymorphism carriers.
58 PD patients out of screened for GBA mutation group
participated in the study of plasma ASN. In this group 4
patients was carriers of N370S mutation and 7 were T369M
polymorphism carriers. 1 patient with mutation and 4 with
polymorphism did not participated in next stages of the study.
In order to preserve the group homogeneity and to eliminate
any possible effect of GBA gene mutation, further assays to
evaluate relation between plasma ASN and the clinical data
were conducted independently for mutation carriers and non-
carriers. Finally in clinical analysis participated 54 PD patients
without mutation.
Additionally 38 healthy volunteers as CG agreed to
participate in the study of plasma ASN. Patients and control
group did not differ in the mean age (respectively 68.43 vs.
64.57 years of age) and sex (female %, respectively: 43.10
vs.44.74). Fig. 1 shows the scheme of the study.
3.2. Plasma ASN concentrations in the patients and in the
healthy volunteers
Based on evaluation of normality of distribution of ASN
concentration in the test group and in the controls, it was
Fig. 1 – The scheme of the study.
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the normal distribution and the comparison made use of the
nonparametric U Mann–Whitney test. The median values of
plasma ASN in the patient group and in the test group show no
signiﬁcant difference (respectively: 4.18 vs 3.73 ng/ml; p = 0.25).
In order to assess the usefulness of ASN concentrations in
PD diagnosis, a ROC curve was drawn. The area under curve
(AUC) does not differ statistically from the area below the
diagonal (AUC = 0.58; p = 0.20), which shows that the variable
(ASN concentration) has no predictive value for the diagnosis
of PD.
There was no correlation between the age, age of the
disease onset or disease duration and plasma ASN in PD
patients.
3.3. Relation between plasma ASN and intensiﬁcation of
PD symptoms
Intensiﬁcation of symptoms was measured with the use of
UPDRS and HY Scale in 53 out of 58 PD patients, in whom
plasma ASN concentration was marked. One patient did not
declare the consent for neurological examination. Results of
the evaluation making use of subsequent parts of UPDRS
Scale (II, III, IV) and HY Scale are presented in Table 1. Validity
of distribution of plasma ASN concentration for normal
distribution was analyzed in the group of patients with PD at
different stage, deﬁned by grades of HY Scale (non-advanced
PD: grade 1–2.5; advanced PD: grade 3–5) and in the controls,
along with correlation between plasma ASN and intensiﬁca-
tion of PD manifestations. In the control group plasma ASN
showed no normal distribution, therefore comparison of ASNconcentrations among the tested groups made use of the
nonparametric Kruskal–Wallis test. No correlation was
shown between the average plasma ASN concentration
and intensiﬁcation of motor symptoms measured by subse-
quent parts of UPDRS. The correlation between plasma ASN
and the stage of disease (HY) was on the verge of signiﬁcance
(Spearman correlation R = 0.26, p = 0.06). Similarly, no
difference was shown between the median plasma ASN in
patients with different stages of the disease and the healthy
controls (Table 2).
3.4. Comparison of ASN concentrations in different motor
subtypes of Parkinson's disease
Out of 53 patients with PD: 40 were patients with subtype PIGD,
6 with TD subtype and 7 with MPD. The clinical characteristics
of patients qualiﬁed for individual types are illustrated in
Tables 3–5.
Distribution of ASN concentrations in PIGD subtype and in
the controls was not valid for normal distribution. Therefore,
evaluation made use of nonparametric Kruskal–Wallis test. No
signiﬁcant differences were shown for the median plasma ASN
in the investigated subtypes, as compared to the controls
( p = 0.46).
Correlation between plasma ASN concentration and the
clinical data (age, age at onset, duration of the disease, UPDRS
II, III, IV, HY) was assessed for each of the tested subtypes
(PIGD, TD and MPD). No correlations were found in subtypes
TD and MPD. In subtype PIGD, only one average negative
correlation of plasma ASN was observed in HY Scale (Spear-
man's correlation R = 0.33; p = 0.04).
Table 1 – Intensification of motor symptoms and advance grade in the tested patient group.
Variable Average SD Median Bottom quartile Upper quartile
aUPDRS II 12.90 10.60 10.00 5.00 17.00
aUPDRS III 29.51 13.12 27.00 19.00 39.00
aUPDRS IV 4.06 3.16 4.00 1.00 5.50
bHY 2.40 0.88 2.00 2.00 3.00
a Unified Parkinson's Disease Rating Scale.
b Hoehn–Yahr Scale.
Table 2 – The comparison of plasma ASN level in different stages of the disease.
The level of plasma ASN (ng/ml)
Group Median Lower quartile Upper quartile Mean SD
Non-advanced PD 4.69 3.05 6.56 4.93 2.35
Advanced PD 3.13 2.20 5.41 3.65 1.70
aCG 3.73 2.75 4.86 3.90 1.56
a Control group.
Table 3 – Clinical characteristics of patients with subtype PIGD of the disease.
Variable PIGD – 40 patients
Average SD Median Minimum Maximum
Age 69.89 10.36 70.00 49 90
Age at onset 58.56 10.77 58.50 40 83
Duration of disease 10.22 4.78 9.00 3 21
UPDRS II 14.30 11.28 10.00 1 46
UPDRS III 30.41 13.79 27.00 10 62
UPDRS IV 4.29 3.12 4.00 0 11
HY 2.51 0.98 2.50 1 5
Table 4 – Clinical characteristics of patients with subtype TD of the disease.
Variable TD – 6 patients
Average SD Median Minimum Maximum
Age 69.17 9.83 70.00 54 82
Age at onset 61.50 9.57 58.50 50 77
Duration of disease 7.67 3.27 7.00 4 12
UPDRS II 8.83 7.55 7.50 2 22
UPDRS III 29.00 11.17 28.00 16 46
UPDRS IV 3.83 3.76 3.00 0 11
HY 2.25 0.27 2.25 2 2.5
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cognitive impairment as well as depressive symptoms in PD
group and healthy volunteers
The characteristics of PD patients and CG in the context of
cognitive impairment and depressive disorder are presented
in Table 6. The comparison of plasma ASN level in PD patients
with cognitive impairment and without as well as with
depressive disorder and without are presented in Table 7.
The cut off in MMSE for cognitive impairment was <26 point
and in HDRS for depressive disorder was ≥17 point.There was no correlation (Spearman for non-parametric)
between plasma ASN level and HDRS and MMSE score in group
of PD patients and CG (see the results in Table 8).
3.6. The relation between the level of plasma ASN and
GBA variant status
Table 8 presents the clinical data of PD patients according to
GBA status.
There was no difference in plasma ASN concentration
between the group of patients with different GBA status
(Table 9).
Table 5 – Clinical characteristics of patients who did not qualify for the disease subtypes (MPD).
Variable MPD – 7 patients
Average SD Median Minimum Maximum
Age 68.86 10.60 67.00 52 85
Age at onset 62.40 12.58 61.00 48 80
Duration of disease 6.00 0.71 6.00 5 7
UPDRS II 10.29 8.75 10.00 1 27
UPDRS III 25.43 12.83 26.00 10 47
UPDRS IV 2.83 3.31 1.50 0 9
HY 1.93 0.61 2.00 1 3
Table 6 – The screening data of cognitive impairment and
depressive symptoms in PD patients and healthy volun-
teers from control group (CG).
Mean  SD PD (N = 51) CG (N = 21) p
MMSE 26.6  4.1 28.5  2.6 0.02
HDRS 7.4  7.3 1.9  3.3 0.02
MMSE – Mnimental State Examination; HDRS – Hamilton Depres-
sion Rating Scale.
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In the presented study, the patients with PD showed higher
plasma ASN concentration than the healthy controls, however
the difference was not statistically signiﬁcant. The studies
published so far have most frequently referred the so-called
ASN total, i.e. independent of conformation and the degree of
protein aggregation. The presented study evaluated plasma
ASN total with the use of commercial ELISA kit, used also for
two other assays.
Duran et al. [9] measured the level of plasma ASN total in PD
patients, treated and untreated, and in the healthy controls.
The groups assessed were slightly larger than those in the
present study. The PD patients showed signiﬁcantly higher
ASN level than the controls, regardless of the drugs received. It
should be noted however, that the patients and the healthy
controls were not selected for age. The controls were younger
than PD patients, both, those who were receiving treatment
and the untreated ones. The publication fails to quote exact
values of the average ASN level in the tested individuals.
Caranci et al. [8] also evaluated plasma ASN total with the
use of the same ELISA kit. The tested group and the control one
were larger than in the present study and the patients were
slightly younger. Included in the study were only patients with
the I–III grade of the disease, according to HY Scale. No
difference in concentrations was proved between the patients
and the healthy controls.
Lee et al. [15] used another commercial ELISA kit to evaluate
plasma ASN total and observed statistically higher concentra-
tions in PD patients than in the healthy controls, however the
groups were larger than in the present study. Moreover, they
showed signiﬁcantly higher concentration of the protein in 38
patients suffering from the Multiple System Atrophy (MSA)
(78.1  3.5 pg/ml). It was also noted that ASN level wassigniﬁcantly higher in PD patients, as compared to those with
MSA.
As the results of studies in ASN total in PD are contradicto-
ry, studies have been initiated to include other ASN forms in
plasma and in the cerebrospinal ﬂuid, such as toxic oligomers
or phosphorylated ASN (following post-translation modiﬁca-
tion). The ﬁrst studies were carried out by El Agnaf et al. [10].
The team created a customized ELISA kit where ASN oligomers
were evaluated in 34 PD patients and in 27 controls, selected
for age and sex. Nevertheless, the controls were recruited
among the patients of the clinical department of haematology
and included individuals suffering from cancer, heart dis-
eases, chronic renal failure or cerebral stroke. The PD patients
showed statistically higher level of ASN oligomers than the
controls, however the authors published no average concen-
trations.
Many authors emphasize that contradictory results are the
effect of contamination of ASN samples originating from
morphotic elements of blood (mainly erythrocytes) [20,31].
However, Ishii et al. hypothesized that nor only haemolysis
contributed to the lack of explicit data, but also the presence of
heterophilic antibodies (HA) in human blood. HA have the
capacity of reacting with animal immunoglobulins as well as
animal borne antigens, which are present in all ELISA kits [14].
Based on the studies quoted, it may be concluded that so far
no efﬁcient technique to measure plasma ASN has been
designed. Particular studies made use of a wide spectrum of
antibodies detecting different ASN forms. The most common
was ELISA method. Additionally, Western Blot and Luminex
were used. It has not been shown which of the techniques is
most useful for ASN detection. Plasma ASN concentrations
were found within a very wide rage at differentiation from
about 80 pg/ml [15] to 0.6 mg/ml [12].
ASN is highly expressed in erythroblasts and reticulocytes.
Moreover, haematopoetic transcription factors GATA-1 and
GATA-2 induce SNCA expression in erythrocytes. SNCA shows
co-expression with four enzymes involved in hem metabolism
[32]. About 98–99% blood ASN in healthy individuals originates
from erythrocytes. It is not known, however, what is the
percentage of distribution of this protein in blood of PD
patients [20,31].
The literature quotes remarkably different results of
plasma ASN. Obviously, there is a need for an appropriate
method to evaluate this protein and to deﬁne in which blood
sections the differences in concentration are the greatest.
In the literature presented, the patient groups were highly
differentiated. It happened that among the recruited controls
were individuals with other neurological conditions [10,17]. In
Table 7 – ASN plasma level (ng/ml) in PD patients with cognitive impairment and with depressive disorder.
Cognitive impairment Depressive disorder p
Yes N = 12, median = 3.6, 2.7–5.8 IR N = 6, median = 6.5, 2.9–8.1 IR 0.7
No N = 39, median = 4.5, 2.9–6.2 IR N = 35, median = 4.5, 2.7–6.3 IR 0.3
Table 8 – The correlation (Spearman) between plasma ASN level and score of cognitive impairment and depressive
disorder.
The relation between plasma ASN level and: PD ( p, rho) CG ( p, rho)
MMSE p = 0.6, rho = 0.08 p = 0.7, rho = 0.07
HDRS p = 0.3, rho = 0.16 p = 0.8, rho = 0.08
Table 9 – Clinical characteristics of PD patients who were N370S mutation carriers (PM), T369M polymorphism (PP) carriers
and non-carriers (NC).
Clinical data PM
(N = 4)
NC
(N = 47)
PP
(N = 7)
Statistics ( p)
Age (years) 68 (65–73.5) 67 (62–75) 73 (61–79) ns.
Age of onset (years) 56.5 (53–59) 57 (50–66) 64 (56–67) ns.
Disease duration (years) 12 (10.5–16) 9 (6–12) 9 (6–13) ns.
UPDRS II (score) 16 (11–25) 10.5 (6–19.5) 5 (3–9) ns.
UPDRS III (score) 37.5 (28–55.5) 27 (19–37.5) 27 (19–42) ns.
UPDRS IV (score) 4 (2–7) 4 (1–6) 3 (1–4) ns.
HY (stage) 2.5 (2–4) 2 (2–3) 2.5 (2–3.5) ns.
MMSE (score) 23 (20–27) 28 (25–29) 28 (27–30) ns.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 2 4 3 – 2 5 1 249the presented study, the patients and the controls were
selected for age and sex. The control group included no
individuals with the burden of CNS diseases.
So far scarce contributions have been published to evaluate
the relation between ASN in peripheral tissues and the clinical
picture of PD. They regarded mainly the motor manifestations.
This has been the ﬁrst study to show a negative correlation
between plasma ASN concentration and the grade of the
disease (HY) in PIGD subtype. The assays which evaluated
such dependency, showed no relation between plasma ASN
level and the grade of the disease [8,9,15,21]. It was not
investigated, however, if such correlation existed in different
subtypes of the disease.
In the study by Shi et al., among the recruited patients,
graded 1–4 in HY Scale, the highest values were shown by
grade 2 patients with the decreasing tendency along with the
more advanced grade. Nevertheless, the correlation was not
statistically signiﬁcant, similarly to the presented study [20].
Caranci also showed no correlation between plasma ASN and
the grade of the disease (HY), however enrolled in his study
were only grade 1–3 (HY) patients. It was proved that grade 1–2
men showed statistically higher ASN than grade 3 men. Also,
negative correlation was observe where the scores were
intensiﬁed in part IV of MDS-UPDRS for male patients [8].
The relations between ASN concentration and disease
stage were also analyzed in research of CSF. Reverse correla-
tion between the stage of disease (HY) and the level of CSF ASN
in the group of PD patients was observed [22,23].
Only in one study they analyzed the relation between the
plasma ASN level and motor subtype, which were akinetic,
with tremor dominance and the one with tremor and
bradykinesia. The patients were assessed with MDS-UPDRS
Scale, but the method of classiﬁcation was not speciﬁed.Among 69 patients in 23 they diagnosed akinetic subtype, 30
with tremor dominance and 13 with mixed symptoms. There
was no difference of plasma ASN level between subtypes [8].
Kang et al. tested Alzheimer disease (AD) markers (Ab1-42,
total tau protein: t-tau, phosphorylated tau protein: p-tau) and
total ASN in CSF of 63 patients with PD and 39 healthy
volunteers. The level of ASN, Ab1-42, p-tau was lower in PIGD
than in TD subtype. The level of all markers was lower in PIGD
subtype, unlike in TD and mixed subtype there was no
difference comparing to healthy volunteers. None of the
markers revealed any relation to cognitive functioning [22].
In the presented study the patients showed diverse grades
of the disease (HY 1–5), therefore it was possible to evaluate
correlation with ASN. No differences in ASN concentrations
were observed in individuals with lower or higher grade of the
disease, yet a decreasing tendency was noted in ASN
concentrations along with the growing grade of the disease,
however this correlation was on the verge of signiﬁcance.
Subsequent stratiﬁcation of the analysis revealed signiﬁcant
negative correlation with the grade of the disease (HY) in
subtype PIGD. This may suggest that subtype with dominance
of axial symptoms should be separated entity.
Despite appropriate selection of the groups in the study
performed, no differences in plasma ASN were proved
between particular PD subtypes. The study was not devoid
of disadvantages. It is likely that the groups designed were too
small which prevented showing the signiﬁcant differences.
The size of the sample was restricted mainly by the consent to
take blood for plasma ASN evaluation and availability of the
valid contact information.
It should be noted however, that the lack of differences in
plasma ASN concentrations between the patients and the
controls may be due to substantial clinical diversity of the
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 2 4 3 – 2 5 1250examined patients. It is confounder for searching the
differences. On the other hand it allows to demonstrate the
relation between two factors. In presented study following
subsequent stratiﬁcation of the analysis revealed the relation
between plasma ASN and disease stage in PIGD subtype.
Similarly to its manifestations, the progression of PD is
heterogenous and depends on a variety of factors. The
prevalence of particular motor subtypes is not deﬁnitely
estimated. In the ﬁrst classiﬁcation made by Jankovic TD type
was up to 55% vs. PIGD 29% [1]. On the other hand last
classiﬁcation based on modiﬁed scales MDS-UPDRS showed
that the prevalence of TD is up to 24% vs. PIGD up to 64% [33].
The PIGD subtype is often more difﬁcult to treat and with
worse reaction to levodopa. Patients in the probe were
recruited in specialized towards movement disorders unit
and probably this is the reason for large proportion of PIGD
subtype in the probe.
The subtype PIGD is associated with more dynamic
progression of the disease, as compared to the remaining
forms [2]. It may be for this very reason that only this subtype
showed correlation between the disease grade and plasma
ASN. The negative correlation may be explained by the disease
progression, more dynamic at the beginning (1–2.5 HY), yet
slowing down at a more advanced stage 3–5 HY) [34]. This is
coherent with pathological investigations which showed that
dopaminergic cells in SNpc decay exponentially with time [35].
Additionally there was no difference of plasma ASN
between the group of PD patients with N370S mutation,
carriers of T369M polymorphism, non-carriers and healthy
volunteers. However there were only 4 PD patients with the
mutation and there was observed trend to higher plasma ASN
concentration according to the mutation status. Probably the
group of mutation carriers was to small. It should be
considered if another form of plasma ASN would be better
marker for PD connected with GBA mutation, for example
oligomers of plasma ASN.
Summing up plasma ASN level is not reliable marker for all
types of PD. Further analysis comparing different forms of
disease with more participants in all groups and with their
stronger homogeneity should be performed. There may be
more confounders than the ASN originated from the mor-
photic elements of blood. It is possible that plasma ASN could
be used as the marker of disease progress only in PIGD subtype.
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